Harel is a seasoned executive and entrepreneur in the healthcare space, where he has an extensive and proven track record of over 15 years of leadership in the corporate world as well as the start-up sector, including positions in the USA, Europe and Israel.
In 2010, Harel founded MEDX Ventures Group LLC, an investment and management firm with offices in the USA, Europe and Israel. Harel founded and serves as the CEO & Chairman of Microbot Medical Ltd., a promising early stage medical device company. In addition, Harel founded and serves as the Chairman of XACT Robotics™ Ltd., another transformational, early stage medical device company, where MEDX is the leading investor. Until 2013, Harel also served on the board of directors at ConTIPI Ltd., which was acquired in 2012 by a leading multinational corporation.
Until 2010, Harel served as a Worldwide Group Marketing Director at Johnson & Johnson (Ethicon Inc., Somerville NJ), overseeing the company’s global strategic marketing. Prior to this, Harel was the Regional Marketing Manager at Johnson & Johnson (Ethicon Inc.), responsible for the strategic marketing for Europe, Middle East and Africa. During his tenure, Harel led both companies to continuous growth in revenues and new product launches (both from internal R&D and M&A). Harel also held several management positions in marketing and sales at Johnson & Johnson Medical Israel.
Harel is a guest speaker for management and innovation courses at leading universities in the USA and Israel, including the Technion – Israel Institute of Technology. Harel holds a Bachelor of Science (BS) from Siena College (USA) and a Master in Business Administration (MBA) from Manchester University (UK).
Founder and President of Shizim Group, Israel’s leading biomed service group.
During the past 30 years, Mr. Bornstein has played key roles in the Israeli biomed industry.
Mr. Bornstein was the General Manager of Bristol-Myers Squibb (Israel), until 1992. He subsequently founded Pharmateam Ltd., an Israeli company that successfully specialized in representing International pharmaceutical companies such as 3M Health Care, G.D. Searle, Shire, Medimmune, United Therapeutics, Forest Laboratories, Goldshield and others. Pharmateam was sold in 2000, when Mr. Bornstein founded Shizim Ltd and through it all its subsidiaries.
Mr. Bornstein’s activity is not only recognized and appreciated in the business world, but also on a national level. He served as the Biotechnology Committee Chairman of USISTC (United States-Israel Science & Technology Commission), and also as a consultant for USISTC (United States-Israel Science & Technology Foundation). Through these organizations Mr. Bornstein has initiated, founded and led a number of major national level projects for the Israeli life-science industry and for the State of Israel. Amongst these: ILSI (Israel Life Science Industry Organization) – the biggest organization in Israel for representing the mutual goals of the Israeli life science community [merged into IATI], and ITTN (Israel Technology Transfer Organization), which serves as the umbrella organization for Israel’s academic Technology Transfer Offices, holding all innovative technologies from the entire Israeli academia.
Mr. Bornstein is a Committee Member at The Life Science Forum of IPCC – the Israeli-Palestinian Chamber of Commerce, and has also served as a member of the Advisory Board – Life Science Industry, The Israel Export & International Cooperation Institute.